Role of nuclear medicine in the European guidelines for prostate cancer / 中华核医学与分子影像杂志

ABSTRACT

Prostate cancer is the most common malignancy of the male genitourinary system. In 2022, the European Association of Urology (EAU) published an update of the guidelines for prostate cancer, following the updating of evidence. The clinical application of nuclear medicine diagnostic and therapeutic techniques in the staging and grading, screening and assessment of prostate cancer, especially metastatic castration-resistant prostate cancer, is becoming more and more valuable. This article aims to introduce the application of nuclear medicine recommended in the 2022 edition of EAU guidelines for prostate cancer based on the latest clinical evidence.